-
Something wrong with this record ?
Serum and lymph pharmacokinetics of nilotinib delivered by yeast glucan particles per os
P. Šalamúnová, T. Krejčí, P. Ryšánek, I. Saloň, J. Kroupová, A. Hubatová-Vacková, J. Petřík, T. Grus, P. Lukáč, P. Kozlík, T. Křížek, O. Dammer, J. Beránek, M. Šíma, O. Slanař, F. Štěpánek
Language English Country Netherlands
Document type Journal Article
- MeSH
- Administration, Oral MeSH
- Glucans * MeSH
- Rats MeSH
- Pyrimidines MeSH
- Saccharomyces cerevisiae * MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Nilotinib is a selective tyrosine-kinase inhibitor approved for the treatment of chronic myeloid leukemia. It is poorly soluble in aqueous media and has a low oral bioavailability. Nilotinib encapsulation into yeast glucan particles (GPs) was investigated in this work as a means of increasing bioavailability. The amorphization of nilotinib in GPs resulted in an increased dissolution rate, which was confirmed by in vitro experiments using biorelevant dissolution media. Simultaneously, GPs containing nilotinib were effectively taken up by macrophages, which was quantified in vitro on cell cultures. The overall oral bioavailability in a rat model was approximately 39 % for nilotinib delivered in a reference formulation (Tasigna) and was almost doubled when delivered in GPs. The contribution of glucan particles to the lymphatic transport of nilotinib was quantified. When delivered by GPs, cumulative nilotinib absorption via the lymphatic system increased by a factor of 10.8 compared to the reference, but still represented arelative bioavailability of only 1.12 %. The cumulative uptake of GPs in the lymph was found to be 0.54 mg after a single dose of 50 mg. Yeast glucan particles can therefore serve as a drug delivery vehicle with a dual function: dissolution rate enhancement by amorphization, and, to asmaller extent, lymphatic delivery due to macrophage uptake.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003874
- 003
- CZ-PrNML
- 005
- 20230703083607.0
- 007
- ta
- 008
- 230418s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijpharm.2023.122627 $2 doi
- 035 __
- $a (PubMed)36693484
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Šalamúnová, Petra $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic
- 245 10
- $a Serum and lymph pharmacokinetics of nilotinib delivered by yeast glucan particles per os / $c P. Šalamúnová, T. Krejčí, P. Ryšánek, I. Saloň, J. Kroupová, A. Hubatová-Vacková, J. Petřík, T. Grus, P. Lukáč, P. Kozlík, T. Křížek, O. Dammer, J. Beránek, M. Šíma, O. Slanař, F. Štěpánek
- 520 9_
- $a Nilotinib is a selective tyrosine-kinase inhibitor approved for the treatment of chronic myeloid leukemia. It is poorly soluble in aqueous media and has a low oral bioavailability. Nilotinib encapsulation into yeast glucan particles (GPs) was investigated in this work as a means of increasing bioavailability. The amorphization of nilotinib in GPs resulted in an increased dissolution rate, which was confirmed by in vitro experiments using biorelevant dissolution media. Simultaneously, GPs containing nilotinib were effectively taken up by macrophages, which was quantified in vitro on cell cultures. The overall oral bioavailability in a rat model was approximately 39 % for nilotinib delivered in a reference formulation (Tasigna) and was almost doubled when delivered in GPs. The contribution of glucan particles to the lymphatic transport of nilotinib was quantified. When delivered by GPs, cumulative nilotinib absorption via the lymphatic system increased by a factor of 10.8 compared to the reference, but still represented arelative bioavailability of only 1.12 %. The cumulative uptake of GPs in the lymph was found to be 0.54 mg after a single dose of 50 mg. Yeast glucan particles can therefore serve as a drug delivery vehicle with a dual function: dissolution rate enhancement by amorphization, and, to asmaller extent, lymphatic delivery due to macrophage uptake.
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a Saccharomyces cerevisiae $7 D012441
- 650 12
- $a glukany $7 D005936
- 650 _2
- $a pyrimidiny $7 D011743
- 650 _2
- $a aplikace orální $7 D000284
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Krejčí, Tereza $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic; Zentiva, k.s, U Kabelovny 130, 102 37 Prague, Czech Republic
- 700 1_
- $a Ryšánek, Pavel $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic
- 700 1_
- $a Saloň, Ivan $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic
- 700 1_
- $a Kroupová, Jiřina $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic
- 700 1_
- $a Hubatová-Vacková, Anna $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic
- 700 1_
- $a Petřík, Jakub $u Zentiva, k.s, U Kabelovny 130, 102 37 Prague, Czech Republic; Department of Analytical Chemistry, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republice
- 700 1_
- $a Grus, Tomáš $u Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 499/2, 128 08 Prague, Czech Republic
- 700 1_
- $a Lukáč, Peter $u Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 499/2, 128 08 Prague, Czech Republic
- 700 1_
- $a Kozlík, Petr $u Department of Analytical Chemistry, Faculty of Science, Charles University, Hlavova 2030/8, 128 43 Prague, Czech Republic
- 700 1_
- $a Křížek, Tomáš $u Department of Analytical Chemistry, Faculty of Science, Charles University, Hlavova 2030/8, 128 43 Prague, Czech Republic
- 700 1_
- $a Dammer, Ondřej $u Zentiva, k.s, U Kabelovny 130, 102 37 Prague, Czech Republic $7 xx0303489
- 700 1_
- $a Beránek, Josef $u Zentiva, k.s, U Kabelovny 130, 102 37 Prague, Czech Republic
- 700 1_
- $a Šíma, Martin $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic
- 700 1_
- $a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague, Czech Republic
- 700 1_
- $a Štěpánek, František $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic. Electronic address: Frantisek.Stepanek@vscht.cz
- 773 0_
- $w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 634, č. - (2023), s. 122627
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36693484 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230703083606 $b ABA008
- 999 __
- $a ok $b bmc $g 1924500 $s 1190083
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 634 $c - $d 122627 $e 20230121 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
- LZP __
- $a Pubmed-20230418
